The SELECT trial found that semaglutide significantly reduces cardiovascular events in individuals with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or changes in HbA1c levels.
Ahead of public meeting, FDA signals flexibility in evaluating smoking cessation treatments
Food and Drug Administration leaders are signaling new flexibility in the agency’s approach to evaluating new therapies to help people stop smoking. In a perspective
October 16, 2024